Mr. Snyder has been at MolecularMD since its inception in 2006, where he served as Head of Sales and Marketing. In 2009, he acted as President and COO, directing strategic planning and organizational growth, and assumed the role of President and CEO in 2014.
With more than 15 years of experience in the life science research and diagnostic fields, Mr. Snyder has worked extensively in supporting new product introductions and rapid market adoption for novel proteomic and genomic technologies.
Prior to joining MolecularMD, Mr. Snyder held leadership positions in a number of venture-backed life science research and diagnostic companies, including President and CEO at Protein Solutions. In 2003, he joined Upstate Technology to lead their Luminex reagent business unit.
Mr. Snyder received a BA in Economics from the University of Virginia and an MBA from the College of William and Mary.
Mr. Dozier joined MolecularMD in 2010 and serves as the acting Chief Financial Officer. He is responsible for managing financial, treasury, accounting and all related matters.
Prior to joining MolecularMD, Mr. Dozier was the Chief Financial Officer for seven companies including Owens & Minor, AMF, Hagler Bailly and Upstate Group.
Mr. Dozier holds a BS in Industrial Engineering and Operation Research from Virginia Tech and an MBA from the Darden School, University of Virginia. He is also a board member and Audit Committee Chair of Community Bankers Trust/Essex Bank.
Glenn A. Miller, Ph.D. Executive Vice President Chief Technology Officer
Dr. Miller joined MolecularMD in 2013 and is Executive Vice President and Chief Technology Officer.
With over 25 years of experience in the clinical laboratory industry and personalized medicine, Dr. Miller has held a number of positions including Vice President and Head of Personalized Healthcare and Biomarker Strategy and Alliances for AstraZeneca Pharmaceuticals and Vice President and General Manager of Genzyme Analytical Services, as well as directing the Research and Development efforts of Genzyme Genetics.
He also sits on the Board of Biomarker Strategies, a tissue-based cancer diagnostics company that is developing the SnapPath™ live tumor cell testing platform. Dr. Miller has served as the Chair of the Personalized Medicine Task Force of the European Biopharmaceutical Enterprises, a specialized group of the European Federation of Pharmaceutical Industry Associations. He has also been a member of the Clinical Sciences Committee of the Personalized Medicine Coalition.
Dr. Miller received his Ph.D. in Experimental Pathology from Roswell Park Memorial Institute, a graduate division of the State University of New York at Buffalo. In addition, he completed his postdoctoral work in molecular hematology and viral leukemogenesis at Memorial Sloan Kettering Cancer Center and molecular genetics at the University of Miami, School of Medicine.
Chad Galderisi, D.O. Executive Vice President/Chief Medical Officer Laboratory Director
Dr. Galderisi is one of the founding scientific members of MolecularMD and currently serves as Laboratory Director and member of the board of directors. He has over 10 years of experience in molecular testing and diagnostic surgical pathway including the direction and oversight of critical laboratory testing for the FDA approval of multiple targeted therapies.
Dr. Galderisi holds a BA in Molecular Biology from Washington and Jefferson College and a DO from Philadelphia College of Osteopathic Medicine. He completed his residency in Anatomic and Clinical Pathology at Penn State/MS Hershey Medical Center and a fellowship in Molecular Genetic Pathology at Oregon Health and Science University.
In addition, he is board certified in Molecular Genetic Pathology and is an Adjunct Assistant Professor at Oregon Health and Science University. Dr. Galderisi is licensed in Washington, Oregon, Massachusetts and New York states.